Faropenem Daloxate NEW

Faropenem Esters Impurity Reference Standards – Accelerating Drug Development & Quality Control

Product Overview
Faropenem Esters, derivatives of Faropenem, are penem-class antibiotics that inhibit bacterial cell wall synthesis, making them effective against drug-resistant infections. To meet the needs of drug R&D, quality analysis, and bioequivalence studies, we offer high-purity Faropenem Esters impurity reference standards, including popular impurities like Impurity 2 (CAS: 106560-13-8), Impurity 18 (CAS: 1690457-78-3), and Impurity 7 (CAS: 120705-68-2).

Key Features

• High Purity: HPLC purity ≥95%, with select batches reaching 98%+. COA reports, HNMR, MS, and HPLC spectra provided.

• Comprehensive Structural Verification: IR, UV, and 2D NMR (COSY, NOESY, HMBC, HMQC) data for unambiguous impurity identification.

• In-Stock Availability: Multiple packaging options (10mg–100g) with expedited shipping for urgent requests.

• Regulatory Support: Impurity source analysis, QC strategy development, and analytical method optimization services.

Applications

• Drug Discovery: Impurity structural elucidation, metabolite profiling, and degradation pathway studies.

• Quality Control: Impurity limit determination, stability testing, and lot-to-lot consistency evaluation.

• Bioequivalence: Impurity spectrum comparison for generic drug development.

Technical Expertise

• Over a decade of experience in impurity R&D, with custom synthesis capabilities.

• Advanced SFC purification technology for complex impurity isolation.

• End-to-end solutions including process scale-up and CMC optimization.